Home » Topics » BioWorld Science

BioWorld Science
RSS

Ambys and Takeda to pioneer first-in-class therapies for the treatment of serious liver diseases

Aug. 9, 2018

Positive topline data presented from the pivotal phase III SONICS study of Recorlev

Aug. 9, 2018

Identification of genetic prognosticators in glioblastoma survivors by NGS

Aug. 9, 2018

FDA approves Poteligeo for two subtypes of cutaneous T-cell lymphoma

Aug. 9, 2018

Positive data announced from phase II extension study of MVA-BN RSV universal vaccine

Aug. 9, 2018

Description of a phase I study evaluating locoregional immunotherapy for ovarian cancer recurrence

Aug. 9, 2018

Medshine Discovery synthesizes WEE1hu inhibitors

Aug. 9, 2018

Researchers present new NR1I2 agonists

Aug. 9, 2018

Bayer patents MKNK1 inhibitors

Aug. 9, 2018

Phase III study of Estelle oral contraceptive meets primary efficacy endpoint

Aug. 9, 2018

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...